UK-US Pharma Deal Eliminates Tariffs, Raises NHS Threshold

The United Kingdom and the United States have reached an agreement to eliminate tariffs on pharmaceutical products imported from the US to the UK for the next three years, in exchange for the National Health Service increasing its spending threshold on new medicines by 25 percent. The deal, announced on Monday, aims to enhance access to innovative treatments while securing tariff-free exports for UK pharmaceuticals valued at around 5 billion pounds annually.

Under the terms, import duties on US medicines and treatments will remain at zero percent, a measure the UK government described as the lowest tariff rate offered to any country. In return, the NHS will raise the cost-effectiveness threshold for approving new drugs, allowing more therapies previously deemed too expensive to be funded. This includes breakthrough cancer treatments and options for rare diseases that might otherwise have been rejected. Starting in 2026, pharmaceutical companies will also reduce repayment rates to the NHS from current levels to 15 percent, a mechanism designed to prevent overspending on branded medicines while providing predictability for the industry.

The agreement follows months of tensions...